• Explore /
  • Poster
  • / Impact of first-line bevacizumab therapy on the efficacy of subsequent anti-epidermal growth factor antibodies (anti-EGFR) in metastatic colorectal cancer (mCRC).

Impact of first-line bevacizumab therapy on the efficacy of subsequent anti-epidermal growth factor antibodies (anti-EGFR) in metastatic colorectal cancer (mCRC).

Abstract Poster

Authors

null

Matthew E. Burge

Royal Brisbane and Women's Hospital, Herston, Australia

Matthew E. Burge , Hui-Li Wong , Belinda Lee , Jeanne Tie , Suzanne Kosminder , Kathryn Maree Field , Ben Tran , Jayesh Desai , Sumitra Ananda , Peter Gibbs

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Citation

J Clin Oncol 34, 2016 (suppl 4S; abstr 685)

DOI

10.1200/jco.2016.34.4_suppl.685

Abstract #

685

Poster Bd #

K4

Abstract Disclosures

Similar Posters

First Author: Benoist Chibaudel

First Author: Emmanuelle Samalin

First Author: David Chan

First Author: Akinori Takagane